Catalyst
Slingshot members are tracking this event:
Cellceutix Phase 2 trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
OTC: CTIX | Community voting in process |
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 24, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Psoriasis, Adverse Events, Primary Endpoint., Prurisol, Pharmacodynamics